Patents by Inventor James David Rodgers

James David Rodgers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors
    Patent number: 6946469
    Abstract: The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, wherein A is selected from NCN, NCONH2, and NOR9. The present invention relates to compounds which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: September 20, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jeffery W. Corbett, James David Rodgers
  • Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors
    Publication number: 20030018039
    Abstract: The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones of formula I: 1
    Type: Application
    Filed: March 27, 2002
    Publication date: January 23, 2003
    Inventors: Jeffery W. Corbett, James David Rodgers
  • Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
    Patent number: 6503898
    Abstract: This invention relates to substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating viral infection. A representative compound of the invention is the compound of formula: wherein R22 and R23 are allyl.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: January 7, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Patrick Yuk-Sun Lam, Prabhakar Kondaji Jadhav, Charles Joseph Eyermann, Carl Nicholas Hodge, George Vincent De Lucca, James David Rodgers
  • 1-(3-aminoindazol-5-yl)-3-butyl-cyclic urea useful as a HIV protease inhibitor
    Patent number: 6451999
    Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable salt forms or prodrugs thereof, which are useful as inhibitors of HIV protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: September 17, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James David Rodgers, Patrick Yuk-Sun Lam
  • A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
    Patent number: 6218386
    Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable salt forms or prodrugs thereof, which are useful as inhibitors of HIV protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: April 17, 2001
    Assignee: Dupont Pharmaceuticals
    Inventors: James David Rodgers, Patrick Yuk-Sun Lam
  • 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
    Patent number: 5932570
    Abstract: The present invention relates to compounds of formulae I and II: ##STR1## or pharmaceutically acceptable salt forms or prodrugs thereof, which are useful as inhibitors of HIV protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: August 3, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: James David Rodgers, Robert Frank Kaltenbach, III
  • Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
    Patent number: 5811422
    Abstract: This invention relates to substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating viral infection. A representative compound of the invention is the compound of formula: ##STR1## wherein R.sup.22 and R.sup.23 are allyl.
    Type: Grant
    Filed: November 22, 1996
    Date of Patent: September 22, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Patrick Yuk-Sun Lam, Prabhakar Kondaji Jadhav, Charles Joseph Eyermann, Carl Nicholas Hodge, George Vincent De Lucca, James David Rodgers